Click to access mobile menu


FDA Issues Consumer Advisory for Dietary Supplements Containing Kava

On March 25, 2002, the Food and Drug Administration (FDA) issued an advisory notifying consumers that kava-containing dietary supplements may be associated with severe liver injury. The FDA reported that kava-containing products have been associated with liver-related injuries, including hepatitis, cirrhosis, and liver failure, in over 25 reports of adverse events in other countries. In the U.S., FDA received a report of a previously healthy young female who required liver transplantation, as well as several reports of liver-related injuries.

CDC Morbidity and Mortality Weekly Report

Other Resources